GlaxoSmithKline logo
Advanced search


Data summary

Access to medicines 2002 2003 2004 2005 2006
Number of countries supplied with preferentially priced ARVs1 50 56 57 56 51
Number of preferentially priced Combivir and Epivir tablets shipped (millions)1 7.9 15.9 67.1 126.3 86.3
Number of generic ARVs supplied by GSK licencees (millions) - - - - 120
GSK Combivir not-for-profit price ($ per day)2 - 1.7 0.65 0.65 0.65
Voluntary licences granted to generic manufacturers for GSK ARVs (cumulative total) - - 6 7 8
Value of products donated through GSK Patient Assistance Program in the US (£ million) 112 125 203 255 200
Research and Development          
Expenditure on R&D (£ billions) 2.9 2.8 2.9 3.1 3.5
GSK animal research facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care 7 7 10 10 103
Number of trials published on the GSK Clinical Trial Register (cumulative total) - - 143 2,125 2,7604
Ethical conduct          
Number of managers completing certification to the GSK Code of Conduct 700 9,000 9,600 >12,000 >12,000
Number of contacts through our ethics compliance channels5 - - 2,580 3,644 5,363
Employment          
Women in management grades (per cent) 32 34 35 35 36
Ethnic diversity - minorities (US, per cent) 19 19.5 19.5 19.6 19.8
Ethnic diversity - ethnic minorities (UK, per cent) - - 15.5 16.8 18.3
Lost time injury and illness rate (cases per 100,000 hours worked) 0.34 0.30 0.30 0.30 0.33
Environment          
Number of contract manufacturers audited 16 28 35 41 36
Energy consumption (million gigajoules) 20 20 19 19 19
Water consumption (million cubic metres) 24 23 21 21 22
Ozone depletion potential from metered dose inhalers (tonnes CFC-11 equivalent)6 1,500 782 464 273 186
Ozone depletion potential from production (tonnes CFC-11 equivalent) 121 72 59 51 23
Ozone depletion potential from refrigeration and other ancillary uses (tonnes CFC-11 equivalent) 7 3 3 3 1
Volatile organic compound emissions (thousand tonnes)7 6 6 5 5 4
Global warming potential from energy sources (thousand tonnes CO2 equivalent)7 1,734 1,750 1,666 1,693 1,666
Hazardous waste disposed (thousand tonnes)7 58 56 69 63 67
Community investment          
Total community investment expenditure
(£ millions)		 239 338 328 380 302
Value of humanitarian product donations, including albendazole (£ millions) 24 116 57 41 38
Number of albendazole tablets donated for prevention of lymphatic filariasis (millions) 64 94 67 136 155

  1. Includes ARVs sold at not-for-profit and discounted prices. We are unable to collect data for the number of patients treated.
  2. Includes delivery costs. The Médecins Sans Frontières pricing report lists the average cost of generic equivalents.
  3. This covers 91 per cent of animals used in GSK facilities. In 2005 we had 14 animal research laboratories. In 2006 we closed a laboratory in Japan, acquired laboratories in Croatia and Canada, and established contracts to use laboratories in Singapore and the US, making a current total of 17 GSK laboratories where we use animals.
  4. 98 per cent of trials completed since the merger which created GSK.
  5. Includes contacts with line managers, compliance officers, our confidential Integrity Helplines or offsite post office box (in the US).
  6. 2002 to 2004 data do not include inhalers made in Asia.
  7. We have changed the way we calculate these data and the previous year's data reflect this change. See full environmental report for details.

    8.  

    Trademarks
    Brand names appearing in italics are trademarks either owned by and/or licensed to GSK or associated companies.
    Mectizan is a registered trademark of Merck & Co.

    * Back to top